The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Is a TP53 mutation always a poor prognostic marker for transplantation in AML?

During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to Justin Loke, University of Birmingham, Birmingham, UK. We asked, Is a TP53 mutation always a poor prognostic marker for transplantation in AML?

Is a TP53 mutation always a poor prognostic marker for transplantation in AML?

Historically, patients with TP53 mutations have been known to have adverse prognostic features even after intensive chemotherapy treatment, rendering the option of allogeneic transplantation of little value to the patient. In this video, Loke reviews transplant variables and other prognostic factors affecting the outcomes of patients with TP53-AML who have undergone allogeneic transplant.

 

Share: